Arbor Capital Management Inc. ADV Buys 395 Shares of Zoetis Inc. (NYSE:ZTS)

Arbor Capital Management Inc. ADV grew its stake in shares of Zoetis Inc. (NYSE:ZTS) by 7.3% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 5,806 shares of the company’s stock after buying an additional 395 shares during the quarter. Arbor Capital Management Inc. ADV’s holdings in Zoetis were worth $986,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Callahan Advisors LLC grew its stake in shares of Zoetis by 90.4% during the fourth quarter. Callahan Advisors LLC now owns 13,105 shares of the company’s stock worth $2,135,000 after buying an additional 6,221 shares during the last quarter. Pensionfund Sabic grew its stake in shares of Zoetis by 55.6% during the fourth quarter. Pensionfund Sabic now owns 11,200 shares of the company’s stock worth $1,825,000 after buying an additional 4,000 shares during the last quarter. CIBC Asset Management Inc grew its stake in shares of Zoetis by 24.1% during the fourth quarter. CIBC Asset Management Inc now owns 237,369 shares of the company’s stock worth $38,617,000 after buying an additional 46,050 shares during the last quarter. PFW Advisors LLC bought a new stake in shares of Zoetis during the fourth quarter worth $1,764,000. Finally, Alberta Investment Management Corp grew its stake in shares of Zoetis by 2,050.0% during the fourth quarter. Alberta Investment Management Corp now owns 30,100 shares of the company’s stock worth $4,904,000 after buying an additional 28,700 shares during the last quarter. Institutional investors own 92.80% of the company’s stock.

Zoetis Price Performance

ZTS stock opened at $161.33 on Monday. The firm has a market cap of $72.24 billion, a price-to-earnings ratio of 29.49, a PEG ratio of 2.78 and a beta of 0.94. The company has a quick ratio of 1.08, a current ratio of 1.75 and a debt-to-equity ratio of 1.09. Zoetis Inc. has a 12-month low of $144.80 and a 12-month high of $200.33. The company’s fifty day simple moving average is $166.82 and its 200 day simple moving average is $176.10.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Thursday, February 13th. The company reported $1.40 earnings per share for the quarter, beating the consensus estimate of $1.37 by $0.03. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. The firm had revenue of $2.32 billion for the quarter, compared to analyst estimates of $2.30 billion. On average, analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Stockholders of record on Monday, April 21st will be issued a dividend of $0.50 per share. The ex-dividend date of this dividend is Monday, April 21st. This represents a $2.00 annualized dividend and a dividend yield of 1.24%. Zoetis’s dividend payout ratio is currently 36.56%.

Insider Activity

In other news, EVP Roxanne Lagano sold 326 shares of the company’s stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $170.00, for a total transaction of $55,420.00. Following the transaction, the executive vice president now owns 15,781 shares in the company, valued at approximately $2,682,770. This represents a 2.02 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Willie M. Reed sold 1,210 shares of the company’s stock in a transaction dated Tuesday, March 11th. The stock was sold at an average price of $166.14, for a total transaction of $201,029.40. Following the completion of the sale, the director now owns 11,245 shares in the company, valued at $1,868,244.30. This represents a 9.71 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 1,862 shares of company stock worth $312,254. Company insiders own 0.16% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently weighed in on ZTS shares. Leerink Partners started coverage on shares of Zoetis in a research note on Monday, December 2nd. They issued an “outperform” rating and a $215.00 price objective on the stock. Morgan Stanley reduced their price objective on shares of Zoetis from $243.00 to $238.00 and set an “overweight” rating on the stock in a research note on Friday, February 14th. Barclays boosted their price objective on shares of Zoetis from $242.00 to $244.00 and gave the stock an “overweight” rating in a research note on Friday, February 14th. Stifel Nicolaus reduced their price objective on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a research note on Tuesday, January 7th. Finally, StockNews.com raised shares of Zoetis from a “hold” rating to a “buy” rating in a research note on Friday, March 7th. One analyst has rated the stock with a hold rating, ten have issued a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $215.90.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.